Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ANA Does Not Improve DFS vs TAM<br />
Disease-free survival, %<br />
No. at risk<br />
TAM<br />
ANA<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
No. of Hazard ratio (95% CI)<br />
events vs TAM P value<br />
ANA 72 1.096 (0.78 to 1.53) .593<br />
TAM 65<br />
0 0 12 24 36 48 60 72 84<br />
Time since randomization, months<br />
900 834 718 552 411 243 129 50<br />
903 844 725 540 411 255 139 51<br />
Median follow-up = 48 months.<br />
DFS = Disease-free survival; CI = Confidence interval; ZOL = Zoledronic acid.<br />
Update of <strong>Gnant</strong> M, et al. Presented at: ASCO 20<strong>08</strong>. Chicago, IL. Abstract LBA4.<br />
9
Change language